TrialBlood advances2026

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.